NAQC Newsroom: Research

Smoking Cessation among US Adults: Use of E-cigarettes, Including JUUL, and NRT Use.

Thursday, October 22, 2020  
Posted by: Natalia Gromov

Patel M, Cuccia AF, Zhou Y, Kierstead EC, Briggs J, Schillo BA.
Smoking Cessation among US Adults: Use of E-cigarettes, Including JUUL, and NRT Use.
Tob Control. 2020 Sep 21:tobaccocontrol-2020-056013. doi: 10.1136/tobaccocontrol-2020-056013. Epub ahead of print. PMID: 32958602. 

Background: Electronic cigarettes (e-cigarettes) are a common tobacco product in the US. Despite lacking Food and Drug Administration (FDA) approval for cessation, e-cigarettes, including JUUL, a popular device, have been viewed by some as a potential tool for tobacco users seeking to quit combustible tobacco use. It is unknown how current and former smokers report using these products for cigarette smoking cessation. Methods: Online surveys were collected from a probability-based panel of US adults aged 18-64, with an oversample of past 12-month JUUL users (n=3415). Weighted past 12-month and past 30-day use of popular e-cigarette brands were measured. Former smokers with a quit attempt in the past 4 years and current smokers with a quit attempt in the past 12 months were asked about methods for smoking cessation, including e-cigarettes and nicotine replacement therapies (NRTs) use.  Results: Among former smokers (n=157), 21.2% used e-cigarettes and/or NRTs to help them quit. Specifically, 2.2% used JUUL only, compared with 10.3% who used NRTs only, and 6.9% used other e-cigarettes only to quit. Among current smokers with a quit attempt (n=308), 24.0% used any product (NRT or e-cigarettes) to quit, and only 1.1% used JUUL only. Current smokers reported relatively low use of NRTs only (10.1%), other e-cigarettes only (5.6%) and other e-cigarettes and NRTs (5.1%). Conclusions: Data suggest that few smokers in the US use e-cigarettes, and JUUL specifically, for cessation, and NRTs use is relatively low. All e-cigarettes should undergo FDA review to minimise recreational use and understand their cessation efficacy.